Use of Highly Encapsulated *Streptococcus pneumoniae* Strains in a Flow-Cytometric Assay for Assessment of the Phagocytic Capacity of Serotype-Specific Antibodies

W. T. M. JANSEN,1* J. GOOTJES,3 M. ZELLE,1 D. V. MADORE,2 J. VERHOEF,1 H. SNIPPE,1 AND A. F. M. VERHEUL1

Eijkman-Winkler Institute for Microbiology, Infectious Diseases and Inflammation, Section Vaccines, Utrecht University Hospital, 3584 CX Utrecht, The Netherlands,1 and Wyeth-Lederle Vaccines and Pediatrics, Rochester, New York 14586-97282

Received 18 December 1997/Returned for modification 9 April 1998/Accepted 9 June 1998

A phagocytosis assay for *Streptococcus pneumoniae* based on flow cytometry (FACS) with human polymorphonuclear cells and human complement was developed for the study of human vaccination antisera. Human prevaccination sera already contain high levels of C-polysaccharide (C-PS) antibodies, which are not protective in humans but which might give false positive results in a flow-cytometry-based assay. Cultures of *S. pneumoniae* grown to log phase on three consecutive days, followed by heat inactivation, yielded stable and highly encapsulated strains for serotypes 6A, 6B, 14, 19F, and 23F. As a result, only serotype-specific antibodies were able to facilitate phagocytosis of these strains, whereas no phagocytosis was observed with antibodies against C-PS or pneumococcal surface proteins. No, or weak, phagocytosis was observed with human prevaccination sera, whereas in general, postvaccination antisera facilitated phagocytosis. A highly significant correlation was observed between enzyme-linked immunosorbent assay titers and FACS phagocytosis titers (r = 0.98, P < 0.001) for serotype 23F pneumococci with human vaccination antisera. For all serotypes, interassay variation was below 10%. Major advantages of this assay over the classical killing assay are that (i) limited amounts of sera are required (10 μl per titration curve), (ii) 600 samples can be processed in one day by one person, and (iii) cells can be fixed and measurement of the samples can be performed up to 1 week later.

A number of pneumococcal saccharide-protein conjugate vaccines are currently under development and entering phase III trials (10, 35). In addition to other tests (enzyme-linked immunosorbent assays [ELISA], avidity-affinity tests), the efficacy of these vaccines is ultimately assessed by comparing the incidence of pneumococcal disease in the vaccinated versus nonvaccinated group. The incidence of disease caused by serotypes included in these multivalent vaccines varies, which makes it difficult to evaluate the efficacy of each component. Moreover, their composition must be adapted depending on the geographical area and probably also over time (13, 15, 25). Therefore, the introduction of this type of vaccine would be enormously facilitated by the availability of assays measuring in vitro parameters that correlate with in vivo protection.

Antibody-complement-dependent phagocytosis is the crucial defense mechanism against *Streptococcus pneumoniae*. The ability of serotype-specific antibodies to provide protection against infections with *S. pneumoniae* is beyond doubt, whereas the protective capacity of anti-pneumococcal surface protein antibodies remains to be established (4). The method most commonly used to measure levels of serotype-specific antibodies in the serum is the ELISA. This method determines the amount and isotype distribution of the antibodies present, but provides no direct information about antibody function. In addition, the correlation between antibody titer and protection depends on the pneumococcal serotype (14, 20, 34). One of the in vitro parameters that therefore provides essential information about the functioning of antibodies is their ability to promote phagocytosis as determined by phagocytosis assays based on flow cytometry (FACS) or radioactivity or classical killing assays (1–3, 8, 11, 16, 18, 21, 26, 30, 33, 37). For human vaccination sera, conflicting data for the relation between antibody response and phagocytosis exist. Most studies have shown a weak or nonexistent relationship between these parameters (7, 17, 19, 22, 26), although a good correlation has also been reported (5, 11). These differences can in part be attributed to the differences in methodology used for measuring phagocytosis, e.g., differences in concentrations of bacteria and sera. More important, however, is the role of anti-cell-wall-polysaccharide (C-PS) antibodies. C-PS antibodies can mask the relationship between phagocytic activity and antibody concentration. Viöarsson et al. demonstrated that the correlation between ELISA titers and phagocytosis titers improved when the antisera were absorbed with C-PS before the antibody concentration was measured (37). Depending on the phagocytosis assay conditions, C-PS antibodies can facilitate phagocytosis (36a). C-PS antibodies, however, are not protective in humans, and human prevaccination sera usually contain high concentrations of these antibodies (9, 24, 27, 28, 31, 36, 37). Therefore, C-PS antibody-mediated phagocytosis should be minimized in phagocytosis assays. In principle, this can be achieved by minimizing the accessibility of C-PS by selecting highly encapsulated strains. An alternative strategy is to pre-absorb the serum with C-PS.

Phagocytosis can be assessed by the classical killing assays and assays based on radioactivity or FACS. Previously, we developed a pneumococcal phagocytosis assay for mouse antisera based on FACS (1, 2). This assay gave an excellent correlation with antibody titers and protection as measured in a mouse challenge model (3). In the present study, this assay
was adapted for use with human sera obtained from persons vaccinated with pneumococcal conjugate vaccines. To determine the best method for minimizing the influence of anti-CPS antibodies, the application of highly encapsulated strains and preabsorption of antiserum with C-PH was evaluated. Highly encapsulated strains (serotypes 6A, 6B, 14, 19F, and 23F) were obtained by growing pneumococcal strains to log phase on three consecutive days (28). As a result, only serotype-specific antibodies were able to promote phagocytosis of these strains. Using these strains, our FACS-based phagocytosis assay gave an excellent correlation with ELISA antibody concentrations. Our assay is now operational for the pediatric pneumococcal serotypes 6A, 6B, 14, 19F, and 23F, but can easily be set up for other serotypes when required.

MATERIALS AND METHODS

Growing of bacteria. *S. pneumoniae* serotype 6A, 6B, 14, 19F, and 23F (ATCC strains; a kind gift of J. Henrichsen and U. B. Sørensen, Statens Serum Institut, Copenhagen, Denmark) were plated on blood agar plates and grown overnight at 37°C in a 5% CO₂ atmosphere. Three milliliter of Todd-Hewitt broth supplemented with 0.5% yeast extract (E. Merck Mikrobiologie, Darmstadt, Germany), was inoculated with the strains (optical density at 660 nm [OD₆₆₀] of 0.05 to 0.08). Bacteria were grown either to log phase, to stationary phase, or to log phase three times in order to obtain highly encapsulated strains. For growing bacteria three times to the log phase, 3 ml of Todd-Hewitt broth supplemented with 0.5% yeast extract and 5% heat-activated human pooled serum was inoculated with *S. pneumoniae* (OD₆₆₀ of 0.05 to 0.08). Cultures were grown 4 to 5 h to the log phase (OD₆₆₀ of approximately 0.5) and then stored overnight at 4°C. For the second culture, 3 ml of fresh medium was inoculated with the stationary culture (OD₆₆₀ of approximately 0.5), grown to the log phase, and stored overnight at 4°C. Likewise, a third culture was started from the second culture and grown to the log phase. Absence of contamination by other organisms was checked by plating the bacteria on blood agar plates. Bacteria from the third culture were washed once with phosphate-buffered saline (PBS) (2.250 × g, 15 min, 4°C) and resuspended in PBS to an OD₆₆₀ of 1.0.

Inactivation of *S. pneumoniae* strains. Before and after inactivation, the bacteria were resuspended in PBS to an OD₆₆₀ of 1.0 (approximately 10⁸ bacteria/ml). Three different methods were evaluated for the inactivation of the pneumococcal autolysins. The first was formaldehyde killing, in which formaldehyde (34 μl per ml of bacterial suspension) was added slowly with stirring. Bacterial suspensions were incubated for 1 h at 37°C, centrifuged, and washed twice with PBS. The second was heat killing, in which bacterial suspensions were incubated for 1 h at 60°C and washed once with PBS. The third method was killing with 70% ethanol, in which bacteria were spun down and resuspended in the same volume with 70% ethanol. After incubation for 1 h at 4°C, the bacteria were washed twice with PBS.

Fluorescence labeling of pneumococcal strains. Bacteria were labeled with a 0.5-mg/ml solution of fluorescein isothiocyanate (FITC, Isomer I; Sigma Chemical Co., St. Louis, Mo.) in PBS for 1 h at 4°C. Bacteria were washed twice with PBS. The third method was killing with 70% ethanol, in which bacteria were spun down and resuspended in the same volume with 70% ethanol. After incubation for 1 h at 4°C, the bacteria were washed twice with PBS.

RESULTS

Effect of pneumococcal growth phase on phagocytosis. Most human antiserum contain antibodies directed against C-PS of *S. pneumoniae* (31), which probably facilitate phagocytosis of poorly encapsulated strains. Therefore, in order to develop a serotype-specific phagocytosis assay, highly encapsulated strains are required. First, the effect of the growth phase on encapsulation was examined. To measure the effect of encapsulation, a strain grown to log phase and a strain grown to stationary phase were opsonized with either a rabbit anti-C-PS antiserum or a serotype-specific polysaccharide/ml. Inhibition was calculated as follows: (phagocytosis titer without inhibitor – phagocytosis titer with inhibitor) × 100%/phagocytosis titer without inhibitor.

**ELISA.** The ELISA was performed as previously described (32). Serotype-specific polysaccharide was obtained from the American Type Culture Collection (Rockville, Md.) for use as antigen. Specimens were preadsorbed with C-poly saccharide-enriched absorbent prepared by Wyeth-Lederle Vaccines and Pediatrics and quantitated against lot 89SF (Center for Biological Research and Evaluation, Food and Drug Administration, Washington, D.C.).

**Statistical analysis.** The coefficient of variation was obtained after log transformation by the following formula: (standard deviation/mean) × 100. Correlations between ELISA titers and FACS phagocytosis titers were analyzed by linear regression tests. Statistical significance of correlations was assessed by Student’s t test. A P value of <0.05 was considered statistically significant.
FIG. 1. (a) PMN cell gating (R1) based on their specific forward (FSC) and right angle (SSC) light scatter. (b) Analysis of phagocytosis of fluorescence-labeled \textit{S. pneumoniae} by PMN cells. The histograms show FITC-positive and -negative PMN cells (discriminated by marker M1) for different serum concentrations: 10% (A), 2% (B), 0.4% (C). Negative controls: PMN cells without serum (D), PMN cells without serum and complement (E), PMN cells only (F).
not shown). However, in general, complete preabsorption of C-PS antibodies with C-PS was difficult to achieve. Therefore, another method was investigated for eliminating the influence of C-polysaccharide antibodies in the FACS-based assay.

**Strains grown to log phase three times.** Nielsen et al. described a method for obtaining highly encapsulated strains by growing strains to log phase three times consecutively (28). Such highly encapsulated strains were tested in the phagocytosis assay with both the serotype-specific and anti-C-PS antisera. The serotype-specific antiserum strongly promoted phagocytosis, whereas almost no phagocytosis was observed with the anti-C-PS antiserum (Fig. 3). Identical results were obtained for serotypes 6A, 6B, 14, and 23F (data not shown).

**Inactivation.** When live strains were used, some C-PS antibody-mediated phagocytosis was observed in some of the experiments. *S. pneumoniae* produces enzymes (autolysins) that can cause lysis of the bacterium and probably also partial release of the capsule (12). Killing the bacteria leads to inactivation of these enzymes (12). Three different methods for killing the pneumococci were evaluated: heat inactivation, killing by ethanol, and killing by formaldehyde. Heat inactivation and formaldehyde treatment both resulted in the absence of phagocytosis with anti-C-PS antibodies, whereas with ethanol treatment some residual phagocytosis was detected (Fig. 4). The strongest phagocytosis with the serotype-specific serum, however, was observed when heat inactivation was used. Therefore, subsequent experiments were performed with heat-inactivated strains grown to log phase three times. Strains treated in this way can be stored at -20°C for at least half a year without losing the properties described above (data not shown).

**Anti-protein antibodies.** In addition to C-PS antibodies, human antisera are expected to contain antibodies to surface proteins of *S. pneumoniae*. Encapsulation will probably influence the ability of these anti-protein antibodies to facilitate phagocytosis. To investigate this possibility, rabbit pre- and
postvaccination sera against hydrophobic pneumococcal proteins of serotypes 4 and 19F pneumococci were used. A serotype 19F strain was grown either to stationary phase or to log phase three times and heat inactivated. The anti-protein antiserum was only able to promote phagocytosis of the stationary grown strain, whereas no phagocytosis was observed with the strain grown to log phase three times (Fig. 5).

Capsular polysaccharide preincubation. To demonstrate that only serotype-specific phagocytic antibodies are detected when heat-inactivated strains grown to log phase three times are used, sera were absorbed with serotype-specific polysaccharide or C-PS. For all serotypes, preincubation of the serotype-specific serum with serotype-specific polysaccharides resulted in a strong inhibition of phagocytosis, whereas no inhibition was observed after serum absorption with C-PS (Fig. 6).

Correlation with ELISA. Phagocytosis of pneumococci is mediated by antibodies in cooperation with complement. To investigate the relationship between antibody concentration and phagocytosis titer, antibody concentrations and phagocytosis titers were determined in 46 human pre- and postvaccination antisera. Sera were heat inactivated, and human IgG-depleted pooled serum was used as an exogenic complement source (Fig. 7). No, or weak, phagocytosis was observed for prevaccination sera, whereas, in general, postvaccination antisera gave phagocytosis. A strong, highly significant correlation was observed between IgG antibody concentrations and phagocytosis titers ($r = 0.98, P < 0.001$). Without complement,
similar results were obtained ($r = 0.97$), but no phagocytosis was observed for prevaccination antisera (data not shown).

**Coefficient of variation.** The reproducibility of the phagocytosis assay for each serotype was determined by measuring the phagocytosis titers of a serotype-specific rabbit antiserum and a human conjugate vaccine antiserum on five different days. For all serotypes, with rabbit antisera, interassay variation was below 5%, whereas human antisera gave an interassay variation below 10% (Table 1).

### DISCUSSION

This report describes a pneumococcal phagocytosis assay which predominantly measures phagocytosis mediated by serotype-specific antibodies. Rabbit hyperimmune antisera directed against either C-PS or surface proteins failed to promote phagocytosis in this assay. Moreover, in contrast to C-PS, only preincubation of the sera with serotype-specific polysaccharide could inhibit phagocytosis.

The accessibility of C-PS on pneumococci was minimized by selecting for highly encapsulated strains. This was achieved by growing the strains three times to the log phase in the presence of 5% human pooled serum (HPS). A possible mechanism for the effect of this procedure is that C-PS antibodies present in the HPS cause agglutination and thereby inhibit growth of poorly encapsulated strains. In this way, each subsequent culture is enriched with highly encapsulated pneumococci. To ensure that every experiment was performed with highly encapsulated pneumococci, stocks of pneumococci were regularly tested for the absence of phagocytosis with the rabbit anti-C-PS antiserum. Therefore, anti-C-polysaccharide antiserum can be used as an easy quality control for strain encapsulation.

When live, highly encapsulated bacterial stocks were used, particularly those of strain 23F, appearance of C-polysaccharide antibody-mediated phagocytosis was observed after freezing and thawing, probably due to the release and activation of pneumococcal enzymes (autolysins). Comparing methods for inactivating these enzymes, such as heat treatment, ethanol fixation, and paraformaldehyde fixation, indicated that heat inactivation for 1 h at 60°C gave the best results (Fig. 4). Strains treated this way gave no phagocytosis with the anti-C-polysaccharide antiserum and the strongest phagocytosis with the serotype-specific antiserum. A potential disadvantage of the use of heat treatment is the potential denaturation of protein epitopes on the pneumococcus. Therefore, when the purpose is to evaluate the opsonic capacity of anti-pneumococcal protein antibodies, live and heat-inactivated strains should initially be compared.

Interassay variation of the FACS-based assay was excellent and in the same range as that recently reported for the classical killing assay in which HL-60 cells were used as a source of phagocytes (33). With rabbit antisera, the interassay variation was below 5% for all serotypes, whereas with human antisera, an interassay variation of around 10% was observed (Table 1). Part of this difference is probably due to Fcγ polymorphisms on the PMN cells used. For testing of the human antisera, care was taken to use donors who were either heterozygous or homozygous for FcγRIIA-131H. These donors, however, possessed different FcγRIIB receptors, which affects the phagocytosis mediated by IgG1 and IgG3 antibodies (NA1/NA2). Rabbits produce only a single type of IgG, and as far as we know, the interaction with human FcγRIIA and FcγRIIB is not dependent on the polymorphisms of these receptors. The influence of FcγRIIA and FcγRIIB polymorphisms on the performance of the phagocytosis assay is currently under investigation in our laboratory.

To evaluate the performance of the FACS-based assay with human antisera, the phagocytic capacities of pre- and postvaccination sera obtained from adults vaccinated with various conjugate vaccines or Pneumovax were determined. Independent of antibody concentrations, no phagocytosis was observed for prevaccination antisera without addition of complement, suggesting that these prevaccination sera probably contained phagocytic IgM antibodies. Comparison of the FACS-based phagocytosis titers and the IgG antibody concentrations demonstrated a strong and highly significant correlation between these two parameters. In this respect, the FACS-based phagocytosis assay adapted for use of human antisera displayed characteristics identical to those of our previously described assay for mouse antisera, in which we used the J774 mouse cell line (2, 3). This assay not only correlated strongly with the serotype-specific IgG and IgM antibody levels but was (in combination with the IgG antibody levels) also the best predictor of survival of vaccinated mice upon challenge with a lethal dose of pneumococcus (3).

The classical killing assay is considered to be the “gold standard” for the assessment of the phagocytic capacity of antisera. That assay, however, is cumbersome to perform, only a limited number of antisera (at most 30) can be processed per assay, and the test has to be evaluated the next day (33). With the FACS-based assay, 600 samples (150 antisera/4 serum dilutions) can be processed in 1 day by one person. Moreover, the
cells can be fixed and the flow cytometry can be performed up to 1 week later. In addition, in the FACS-based assay, the results are measured by a machine and analyzed by computer, whereas with the classical killing assay, the colonies are scored by eye, leading more easily to human errors. Moreover, the use of antibiotics by patients or vaccinated people affects the outcome of the killing assay. The FACS-based assay uses inactivated strains and is therefore not affected by the presence of antibiotics.

Upon comparison of our FACS-based assay with the killing assays described in the literature, at first sight, our FACS-based assay seems to be less sensitive (33). There are, however, essential differences between both assays. To avoid bacterial outgrowth, effector/target ratios used in classical killing assays vary from 100:1 to 500:1, and baby rabbit serum is utilized as the complement source. The FACS-based assay uses an effector/target ratio of 1:10 and human complement. At the moment, it is difficult to establish what type of assay correlates best with in vivo protection in humans or animals, but effector/target cell ratios during pneumococcal infections of 100:1 to 500:1 seem to be less likely compared to an effector/target ratio of 1:10. In addition, the FACS-based assay for mouse antisera is an excellent predictor of the survival of vaccinated mice after challenge with pneumococci (3). The question raised above, however, can probably be answered only at the end of the current phase III pneumococcal conjugate trials. Large numbers of antisera have to be evaluated for their phagocytic capacity, and the correlation with protection has to be established. In particular, sera obtained from toddlers who are infected with S. pneumoniae despite having been vaccinated will be important to study. At the moment, we are in the process of setting up interlaboratory studies on the correlation between FACs phagocytosis titers and classical killing titers.

In conclusion, the FACS-based assay is an easy-to-perform method for measuring the phagocytic capacity of large numbers of pneumococcal vaccine antisera. It has low interassay variation and displays a good correlation with postvaccination IgG concentrations.

ACKNOWLEDGMENTS

We thank G. Rijkers, Department of Immunology, Wilhelmina kinderziekenhuis, University Hospital for Children and Youth, Utrecht, and K. Overweg, Laboratory of Pediatrics, Erasmus University, Rotterdam, for providing antisera; J. van der Winkel and N. Westerdal, kinderziekenhuis, University Hospital for Children and Youth, Utrecht, U. B. Sørensen, Statens Seruminstitut, Copenhagen, Denmark, for IgG concentrations.

We thank G. Rijkers, Department of Immunology, Wilhelmina kinderziekenhuis, University Hospital for Children and Youth, Utrecht, and K. Overweg, Laboratory of Pediatrics, Erasmus University, Rotterdam, for providing antisera; J. van der Winkel and N. Westerdal, kinderziekenhuis, University Hospital for Children and Youth, Utrecht, U. B. Sørensen, Statens Seruminstitut, Copenhagen, Denmark, for IgG concentrations.
28. Nielsen, S. V., U. B. Sorensen, and J. Henrichsen. 1993. Antibodies against pneumococcal C-polysaccharide are not protective. Microb. Pathog. 14:299–305.
29. Obaro, S. K., D. C. Henderson, and M. A. Monteil. 1996. Defective antibody-mediated opsonisation of S. pneumoniae in high risk patients detected by flow cytometry. Immunol. Lett. 49:83–89.
30. Paoletti, L. C., D. L. Kasper, F. Michon, J. DiFabio, H. J. Jennings, T. D. Tosteson, and M. R. Wessels. 1992. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J. Clin. Invest. 89:203–209.
31. Pedersen, F. K., J. Henrichsen, U. B. Sorensen, and J. L. Nielsen. 1982. Anti-C-carbohydrate antibodies after pneumococcal vaccination. Acta Pathol. Microbiol. Immunol. Scand. Sect. C 90:353–355.
32. Quataert, S. A., C. S. Kirch, L. J. Quackenbush Wiedl, D. C. Phipps, S. Strohmeyer, C. O. Cimino, J. Skuse, and D. V. Madore. 1995. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2:590–597.
33. Romero-Steiner, S., D. Libutti, L. B. Pais, J. Dykes, P. Anderson, J. C. Whitin, H. L. Keyserling, and G. M. Carlone. 1997. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Diagn. Lab. Immunol. 4:415–422.
34. Schiffman, G., R. M. Douglas, M. J. Bonner, M. Robbins, and R. Austrian. 1980. A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J. Immunol. Methods 33:133–144.
35. Shelly, M. A., H. Jacoby, G. J. Riley, B. T. Graves, M. Pichichero, and J. J. Tetreau. 1997. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect. Immun. 65:242–247.
36. Sjögren, A., B. Lindholm, and T. Holme. 1987. Availability of reaction with antibodies of the pneumococcal C-polysaccharide on the surface of capsulated pneumococci. Acta Pathol. Microbiol. Immunol. Scand. Sect. B 95:371–378.
36a. Verheul, A. F. M., et al. Unpublished results.
37. Viöarsson, G., I. Jonsdottir, S. Jonsson, and H. Valdimarsson. 1994. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J. Infect. Dis. 170:592–599.